Abstract: To complete a transfer of solid material such as mulch, multiple hoses may have to be connected together, therefore, such hoses have hose connection fittings attached at their ends. A hose connector has a male fitting connected to a first hose and a female fitting connected to the second hose. The male fitting may be inserted into the female fitting and the two fittings are secured together thereby connecting a first hose to a second hose. The hose connector has a locking assembly consisting of set screw, a radial hole defined in the female fitting, and a recess for receiving the set screw in the male fitting.

Abstract: The present disclosure relates to fluid bed processes that utilize silica particles as a fluidization aid. The process comprises reacting one or more reactants in a reactor comprising a fluid bed to form a product. The fluid bed comprises a catalyst composition comprising a catalyst and an inert additive composition comprising silica particles from 0.5 wt % to 30 wt %, based on the total weight of the catalyst composition. The silica particles are discrete, inert particles that are mixed with the catalyst in the fluid bed.

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Abstract: The present disclosure relates to fluid bed processes that utilize silica particles as a fluidization aid. The process comprises reacting one or more reactants in a reactor comprising a fluid bed to form a product. The fluid bed comprises a catalyst composition comprising a catalyst and an inert additive composition comprising silica particles from 0.5 wt % to 30 wt %, based on the total weight of the catalyst composition. The silica particles are discrete, inert particles that are mixed with the catalyst in the fluid bed.

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Abstract: The present disclosure relates to fluid bed processes that utilize silica particles as a fluidization aid. The process comprises reacting one or more reactants in a reactor comprising a fluid bed to form a product. The fluid bed comprises a catalyst composition comprising a catalyst and an inert additive composition comprising silica particles from 0.5 wt % to 30 wt %, based on the total weight of the catalyst composition. The silica particles are discrete, inert particles that are mixed with the catalyst in the fluid bed.

Abstract: Disclosed herein are certain 2-oxoquinazoline derivatives of Formula (IA): that are methionine adenosyltransferase 2A (MAT2A) inhibitors. Also disclosed are pharmaceutical compositions comprising such compounds and methods of treating diseases treatable by inhibition of MAT2A such as cancer, including cancers characterized by reduced or absence of methylthioadenosine phosphorylase (MTAP) activity.

Abstract: The present disclosure relates to a process for preparing polymers using a plug flow reactor. The process includes providing an aqueous monomer solution comprising amide monomers; evaporating the aqueous monomer solution to form a concentrated monomer solution; and polymerizing the concentrated monomer solution in a plug flow reactor comprising a shell side and a tube side to form a first process fluid comprising polymers. The concentrated monomer solution flows on the shell side from the inlet to the outlet.

Abstract: A method, a computer program product, and a device that includes one or more processors, a touchscreen, and an operating system. A first dialogue interface is displayed on the touchscreen for receiving user commands by a user touching the dialogue interface. Received user commands are ignored for a defined first period of time in response to the operating system causing a generation of a second dialogue interface on the touchscreen, wherein the defined first period of time is a function of a user interaction with the touch screen by the user.

Abstract: The invention provides a method of aggregate banding comprising defining an aggregate banding dimension for a first data source, the aggregate banding dimension including at least one aggregation variable, at least one banding variable, and at least one band based at least partly on the at least one banding variable; summarizing the data source based at least partly on the at least one aggregation variable, the summary including at least one distinct value of the at least one aggregation variable; and defining a mapping relationship of the at least one distinct value of the at least one aggregation variable to the or respective band(s) based on the value of the at least one banding variable. The invention further provides related systems and processor-executable instructions.

Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.

Abstract: The present disclosure relates to fluid bed processes that utilize silica particles as a fluidization aid. The process comprises reacting one or more reactants in a reactor comprising a fluid bed to form a product. The fluid bed comprises a catalyst composition comprising a catalyst and an inert additive composition comprising silica particles from 0.5 wt % to 30 wt %, based on the total weight of the catalyst composition. The silica particles are discrete, inert particles that are mixed with the catalyst in the fluid bed.

Abstract: A software program is executed, the software program requiring one or more physical interactions with a user through an input/output (I/O) device, wherein each of the one or more physical interactions includes respective predefined dimensions indicating a proficiency in performing one of the one or more physical interactions. The one or more physical interactions are tracked. A familiarity profile for each of the one or more physical interactions is generated based on the respective predefined dimensions for each of the one or more physical interactions. The software program is customized based on the familiarity profile for each of the one or more physical interactions.

Abstract: A software program is executed, the software program requiring one or more physical interactions with a user through an input/output (I/O) device, wherein each of the one or more physical interactions includes respective predefined dimensions indicating a proficiency in performing one of the one or more physical interactions. The one or more physical interactions are tracked. A familiarity profile for each of the one or more physical interactions is generated based on the respective predefined dimensions for each of the one or more physical interactions. The software program is customized based on the familiarity profile for each of the one or more physical interactions.

Abstract: The present invention provides a compound of formula I; wherein R1 is an alkyl pyrazole or an alkyl carboxamide, and R2 is a hydroxycycloalkyl; or a pharmaceutically acceptable salt thereof, and compositions containing these compounds, for use to treat a brain tumor, particularly glioblastoma. The invention provides effective treatment of a brain tumor and can be used by oral administration of a compound of Formula I as further described herein. The invention also provides a method to treat a subject having a brain tumor such as glioblastoma, wherein the method comprises administering to the subject an effective amount of a compound of Formula I. Gene signatures correlated with successful treatment using these methods are also disclosed.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: A method and apparatus for initiating secure operations in a microprocessor system is described. In one embodiment, one initiating logical processor initiates the process by halting the execution of the other logical processors, and then loading initialization and secure virtual machine monitor software into memory. The initiating processor then loads the initialization software into secure memory for authentication and execution. The initialization software then authenticates and registers the secure virtual machine monitor software prior to secure system operations.

Abstract: A software program is executed, the software program requiring one or more physical interactions with a user through an input/output (I/O) device, wherein each of the one or more physical interactions includes respective predefined dimensions indicating a proficiency in performing one of the one or more physical interactions. The one or more physical interactions are tracked. A familiarity profile for each of the one or more physical interactions is generated based on the respective predefined dimensions for each of the one or more physical interactions. The software program is customized based on the familiarity profile for each of the one or more physical interactions.